Pharmaceutical industry – Page 3
-
OpinionMaking chemicals safe and sustainable
The green transition is an opportunity to also make industry simpler and safer
-
BusinessBig deals confirm renewed interest in radiopharmaceuticals
Acquisitions of RayzeBio and Point Biopharma highlight the potential of targeting radioactivity directly to tumour cells
-
BusinessNovo Holdings to buy contract manufacturer Catalent for $16.5 billion
Parent firm will then sell on three manufacturing sites to Novo Nordisk to boost capacity for diabetes and weight loss drugs
-
BusinessUS industry leaders repeat calls to reinstate security programme
Six month gap in vetting people with access to high-risk chemicals means potential threats may have been missed
-
OpinionHarnessing fear and greed for innovation
Many powerful emotions motivate us in the search for new knowledge
-
BusinessNew Covid-19 antiviral cuts symptoms by 1.5 days
Simnotrelvir already has emergency approval in China
-
WebinarUnlocking the future of the chemical industry: the transformative potential of biocatalysis
Learn how scientists are addressing the use of biocatalysis or chemoenzymatic catalysis within industry
-
BusinessIllumina to give up Grail as competition appeals fail
Sequencing giant will sell off its former spin-out in accordance with regulator orders
-
BusinessPharmaceuticals roundup 2023
Regulatory and pricing reforms have topped industry agendas in 2023, while weight loss drugs surged and Covid-19 therapies waned
-
BusinessDanaher completes $5.7 billion Abcam acquisition
Deal proceeded despite significant opposition from founder and ex-chief Jonathan Milner
-
BusinessLife-saving cancer gene therapy under investigation after being linked to rare secondary cancers
US drug agency examining six CAR-T therapies after reports of T-cell malignancies
-
OpinionCompounding problems
Regulating the line between a vital service and grey-market profiteering is a mess
-
BusinessUK becomes first country in the world to authorise a Crispr-based gene therapy
Treatment aims to cure patients with β-thalassaemia and sickle-cell disease
-
BusinessWeight-loss drug shortages prompt copycats and counterfeits
Novo Nordisk and Eli Lilly have struggled to meet huge demand for new hormone mimic obesity treatments
-
OpinionSlow march of the retrosynthesis robots
Software synthesis suggestions are hampered by biased and incomplete datasets
-
BusinessBuilding the support infrastructure we wish we’d had
Harry Destecroix of Science Creates is the 2023 Chemistry World Entrepreneur of the Year
-
BusinessUS regulator says phenylephrine is ineffective as a decongestant
FDA will begin consultation on removing the drug from hundreds of over-the-counter remedies
-
-
BusinessAddressing the saga of nitrosamine contamination in drugs
Scientific and regulatory progress is helping minimise the impact of mutagenic impurities
-
BusinessPositive trial sets stage for therapeutic use of MDMA in US
Hallucinogen-assisted psychiatric treatment heads to regulators, amid cost and other concerns